|
1.
|
学術雑誌(原著)
|
Metabolic tumor volume on 18F-fluorodeoxyglucose uptake as prognostic marker for osimertinib in patients with non-small cell lung cancer harboring sensitive EGFR mutation. 2025/12/31
|
|
2.
|
学術雑誌(症例報告)
|
G-CSF-producing pulmonary sarcomatoid carcinoma treated with chemoradiotherapy followed by durvalumab: a case report. 2025/12/02
|
|
3.
|
学術雑誌(原著)
|
Th7R predicts chemo-immunotherapy response and survival in small cell lung cancer. 2025/12/02
|
|
4.
|
学術雑誌(症例報告)
|
A Case of Combined Small-cell Carcinoma and Adenocarcinoma of the Lung With EGFR Exon 19 Deletion Identified via Liquid Genomic Profiling. 2025/11
|
|
5.
|
学術雑誌(原著)
|
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression. 2025/11
|
|
6.
|
学術雑誌(原著)
|
Eosinophils as predictive biomarkers in anti-programmed cell death 1 monotherapy for non-small cell lung cancer. 2025/10/07
|
|
7.
|
学術雑誌(原著)
|
Prognostic biomarkers for extensive-stage small cell lung cancer receiving amrubicin following failure of chemoimmunotherapy: a retrospective cohort study. 2025/09/30
|
|
8.
|
学術雑誌(原著)
|
Impact of Tumoral β2-Adrenergic Receptor Expression on Chemotherapeutic Response and Prognosis in Patients with Advanced Colorectal Cancer. 2025/09/28
|
|
9.
|
学術雑誌(原著)
|
Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations. 2025/07/12
|
|
10.
|
学術雑誌(原著)
|
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer. 2025/07/05
|
|
11.
|
学術雑誌(原著)
|
Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study. 2025/07/01
|
|
12.
|
学術雑誌(総説)
|
Towards the development of next-generation lung cancer immunotherapy. 2025/06/30
|
|
13.
|
学術雑誌(原著)
|
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED). 2025/06/16
|
|
14.
|
学術雑誌(原著)
|
Pathological Investigation of Grasping-related Mesenteric Injury During Laparoscopic Colorectal Cancer Resection. 2025/06/01
|
|
15.
|
学術雑誌(総説)
|
Clinical significance of mirtazapine for anorexia in patients with non-small cell lung cancer. 2025/05/30
|
|
16.
|
学術雑誌(原著)
|
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression. 2025/05/30
|
|
17.
|
学術雑誌(原著)
|
Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy. 2025/05/30
|
|
18.
|
学術雑誌(原著)
|
Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study. 2025/05/27
|
|
19.
|
学術雑誌(症例報告)
|
Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer. 2025/05/01
|
|
20.
|
学術雑誌(原著)
|
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan. 2025/04/30
|
|
21.
|
学術雑誌(原著)
|
Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer. 2025/04/30
|
|
22.
|
学術雑誌(原著)
|
The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer. 2025/04/05
|
|
23.
|
学術雑誌(原著)
|
A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab. 2025/04/01
|
|
24.
|
学術雑誌(原著)
|
Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer. 2025/04/01
|
|
25.
|
学術雑誌(原著)
|
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study. 2025/04/01
|
|
26.
|
学術雑誌(原著)
|
Serum galectin-3 as a biomarker of progression of idiopathic pulmonary fibrosis treated with nintedanib. 2025/03/18
|
|
27.
|
学術雑誌(原著)
|
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial. 2025/03/01
|
|
28.
|
学術雑誌(原著)
|
Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer. 2025/02/01
|
|
29.
|
学術雑誌(原著)
|
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients. 2025/01/25
|
|
30.
|
学術雑誌(原著)
|
Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. 2025/01/23
|
|
31.
|
学術雑誌(原著)
|
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study. 2025/01/04
|
|
32.
|
学術雑誌(原著)
|
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. 2024/11/27
|
|
33.
|
学術雑誌(原著)
|
Clinical Significance of FAM83G in Breast Cancer: Association With Triple-negative Subtype and Prognosis. 2024/11/01
|
|
34.
|
学術雑誌(原著)
|
A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A. 2024/10/01
|
|
35.
|
学術雑誌(原著)
|
Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors. 2024/09/01
|
|
36.
|
学術雑誌(原著)
|
Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma. 2024/09/01
|
|
37.
|
学術雑誌(原著)
|
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL). 2024/07/07
|
|
38.
|
学術雑誌(症例報告)
|
Membranous Nephropathy as a Paraneoplastic Syndrome in Cancer of Unknown Primary. 2024/06/01
|
|
39.
|
学術雑誌(症例報告)
|
Small cell lung carcinoma initially presenting as giant left ventricular mass. 2024/05/09
|
|
40.
|
学術雑誌(原著)
|
Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study. 2024/05/01
|
|
41.
|
学術雑誌(症例報告)
|
Kaira K, Imai H, Mouri A, Yamaguchi OU, Kagamu H. 2024/05/01
|
|
42.
|
学術雑誌(原著)
|
Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab. 2024/04/03
|
|
43.
|
学術雑誌(原著)
|
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study. 2024/04/01
|
|
44.
|
学術雑誌(症例報告)
|
Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma. 2024/03/01
|
|
45.
|
学術雑誌(原著)
|
Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051. 2024/02/15
|
|
46.
|
学術雑誌(原著)
|
Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
Y 2024/02/01
|
|
47.
|
学術雑誌(症例報告)
|
MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer. 2024/02/01
|
|
48.
|
学術雑誌(原著)
|
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel. 2024/02/01
|
|
49.
|
学術雑誌(原著)
|
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L). 2024/01/27
|
|
50.
|
学術雑誌(原著)
|
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study). 2024/01/01
|
|
51.
|
学術雑誌(原著)
|
The oncogenic role of LGR6 overexpression induced by aberrant Wnt/β-catenin signaling in lung cancer. 2024/01/01
|
|
52.
|
学術雑誌(原著)
|
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. 2023/11/27
|
|
53.
|
学術雑誌(原著)
|
Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib. 2023/11/01
|
|
54.
|
学術雑誌(原著)
|
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101). 2023/11/01
|
|
55.
|
学術雑誌(原著)
|
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed. 2023/09/01
|
|
56.
|
学術雑誌(原著)
|
Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab. 2023/05/25
|
|
57.
|
学術雑誌(原著)
|
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). 2023/05/01
|
|
58.
|
学術雑誌(症例報告)
|
Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma. 2023/05
|
|
59.
|
学術雑誌(原著)
|
Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status. 2023/04/01
|
|
60.
|
学術雑誌(原著)
|
A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer. 2023/03/01
|
|
61.
|
学術雑誌(原著)
|
Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer. 2023/03/01
|
|
62.
|
学術雑誌(原著)
|
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer. 2023/02/02
|
|
63.
|
学術雑誌(原著)
|
Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy. 2023/01/30
|
|
64.
|
学術雑誌(原著)
|
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer. 2023/01/20
|
|
65.
|
学術雑誌(原著)
|
Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study. 2022/12/30
|
|
66.
|
学術雑誌(原著)
|
A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab 2022/12/29
|
|
67.
|
学術雑誌(原著)
|
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. 2022/12/18
|
|
68.
|
学術雑誌(原著)
|
Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. 2022/12/17
|
|
69.
|
学術雑誌(原著)
|
Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy. 2022/12/16
|
|
70.
|
学術雑誌(原著)
|
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival. 2022/12/01
|
|
71.
|
学術雑誌(原著)
|
Potential of VEGFR2 expression as a predictive marker of PD‑1 blockade in patients with advanced NSCLC. 2022/12/01
|
|
72.
|
学術雑誌(原著)
|
Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade. 2022/10/01
|
|
73.
|
学術雑誌(原著)
|
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. 2022/10/01
|
|
74.
|
学術雑誌(症例報告)
|
Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa-associated lymphoid tissue lymphoma: A case report. 2022/10/01
|
|
75.
|
学術雑誌(原著)
|
Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non-small cell lung cancer treated with intensity modulated radiotherapy. 2022/10/01
|
|
76.
|
学術雑誌(原著)
|
Identification and molecular analysis of RNF31 Q622H germline polymorphism. 2022/09/21
|
|
77.
|
学術雑誌(総説)
|
Advanced Research on Immune Checkpoint Inhibitor Therapy. 2022/09/14
|
|
78.
|
学術雑誌(総説)
|
Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment. 2022/08/20
|
|
79.
|
学術雑誌(原著)
|
A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients. 2022/08/01
|
|
80.
|
学術雑誌(原著)
|
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study). 2022/07/29
|
|
81.
|
学術雑誌(原著)
|
Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer. 2022/07/14
|
|
82.
|
学術雑誌(総説)
|
Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer. 2022/06/15
|
|
83.
|
学術雑誌(原著)
|
The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis. 2022/06/06
|
|
84.
|
学術雑誌(原著)
|
Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma. 2022/05/05
|
|
85.
|
学術雑誌(原著)
|
Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer. 2022/05/01
|
|
86.
|
学術雑誌(原著)
|
Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer. 2022/05/01
|
|
87.
|
学術雑誌(原著)
|
Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. 2022/02/17
|
|
88.
|
学術雑誌(原著)
|
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer. 2022/01/01
|
|
89.
|
学術雑誌(症例報告)
|
Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report. 2021/11
|
|
90.
|
学術雑誌(原著)
|
Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study). 2021/10/31
|
|
91.
|
学術雑誌(原著)
|
Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung. 2021/10/12
|
|
92.
|
学術雑誌(原著)
|
Insulinoma-associated protein 1 (INSM1) expression in breast carcinomas with neuroendocrine morphologies: application and future prospective 2021/07
|
|
93.
|
学術雑誌(症例報告)
|
Synchronous dilemma of sarcoid-like reaction and drastic response after PD-1 blockade administration in lung cancer. 2021/06/01
|
|
94.
|
学術雑誌(総説)
|
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma. 2021/03/03
|
|
95.
|
学術雑誌(原著)
|
Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. 2021/03/01
|
|
96.
|
学術雑誌(原著)
|
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). 2021/02/27
|
|
97.
|
学術雑誌(その他)
|
Re: INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer 2021/02
|
|
98.
|
学術雑誌(原著)
|
Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab. 2021/01/21
|
|
99.
|
学術雑誌(原著)
|
Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. 2021/01/13
|
|
100.
|
学術雑誌(症例報告)
|
Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features 2020/12
|
|
101.
|
学術雑誌(原著)
|
Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma 2020/07/01
|
|
102.
|
学術雑誌(原著)
|
Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer 2020/07
|
|
103.
|
学術雑誌(原著)
|
FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer 2020/06/01
|
|
104.
|
学術雑誌(原著)
|
Prognostic significance of β2-adrenergic receptor expression in patients with surgically resected colorectal cancer 2020/06/01
|
|
105.
|
学術雑誌(原著)
|
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events 2020/05/01
|
|
106.
|
学術雑誌(原著)
|
Diagnostic value of 18 F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8 + tumour-infiltrating lymphocytes in oral squamous cell carcinoma 2020/05/01
|
|
107.
|
学術雑誌(症例報告)
|
Verrucous skin lesion caused by neuropathy misdiagnosed as squamous cell carcinoma and treated with amputation surgery 2020/05/01
|
|
108.
|
学術雑誌(原著)
|
Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study 2020/04/01
|
|
109.
|
学術雑誌(原著)
|
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer 2020/04/01
|
|
110.
|
学術雑誌(症例報告)
|
Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib 2020/04/01
|
|
111.
|
学術雑誌(原著)
|
Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([ 18 F]FAMT) Uptake in Patients with Lung Cancer 2020/04/01
|
|
112.
|
学術雑誌(原著)
|
Immunological and Clinicopathological Significance of MFG-E8 Expression in Patients with Oral Squamous Cell Carcinoma 2020/04
|
|
113.
|
学術雑誌(原著)
|
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer 2020/03/07
|
|
114.
|
学術雑誌(原著)
|
Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC 2020/03/01
|
|
115.
|
学術雑誌(症例報告)
|
Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review 2020/03/01
|
|
116.
|
学術雑誌(原著)
|
CD4 + T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy 2020/03
|
|
117.
|
学術雑誌(総説)
|
Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients 2020/03
|
|
118.
|
学術雑誌(原著)
|
High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors 2020/03
|
|
119.
|
学術雑誌(原著)
|
Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin 2020/02/11
|
|
120.
|
学術雑誌(原著)
|
Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma 2020/02/01
|
|
121.
|
学術雑誌(原著)
|
Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer 2020/02/01
|
|
122.
|
学術雑誌(原著)
|
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer 2020/02
|
|
123.
|
学術雑誌(原著)
|
Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study 2020/01/25
|
|
124.
|
学術雑誌(原著)
|
Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma 2020/01
|
|
125.
|
学術雑誌(症例報告)
|
Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer 2020/01
|
|
126.
|
学術雑誌(症例報告)
|
Unexpected response of extramedullary plasmacytoma in patients with lung cancer who received nivolumab 2019/12/01
|
|
127.
|
学術雑誌(原著)
|
Save Email Send to
Thorac Cancer
. 2019 Dec;10(12):2200-2208. doi: 10.1111/1759-7714.13193. Epub 2019 Oct 8.
Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors 2019/12
|
|
128.
|
学術雑誌(原著)
|
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer 2019/10
|
|
129.
|
学術雑誌(原著)
|
Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma 2019/10
|
|
130.
|
学術雑誌(原著)
|
Fucosylated α 1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer 2019/10
|
|
131.
|
学術雑誌(原著)
|
β 2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer 2019/10
|
|
132.
|
学術雑誌(原著)
|
Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study 2019/09
|
|
133.
|
学術雑誌(原著)
|
Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death 2019/07
|
|
134.
|
学術雑誌(原著)
|
Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors 2019/07
|
|
135.
|
学術雑誌(原著)
|
Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma 2019/06
|
|
136.
|
学術雑誌(症例報告)
|
Drastic Response of Re-challenge of EGFR-TKIs Immediately After Nivolumab Therapy in EGFR-TKI-Resistant Patients 2019/06
|
|
137.
|
学術雑誌(原著)
|
Prognostic significance and population dynamics of peripheral monocytes in patients with oropharyngeal squamous cell carcinoma 2019/06
|
|
138.
|
学術雑誌(症例報告)
|
Koga Y, Hachisu Y, Tsurumaki H, Yatomi M, Kaira K, Ohta S, Ono J, Izuhara K, Dobashi K, Hisada T. 2019/05/17
|
|
139.
|
学術雑誌(原著)
|
An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer 2019/05
|
|
140.
|
学術雑誌(原著)
|
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation 2019/05
|
|
141.
|
学術雑誌(原著)
|
Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer 2019/05
|
|
142.
|
学術雑誌(原著)
|
Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer 2019/04
|
|
143.
|
学術雑誌(原著)
|
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer 2019/04
|
|
144.
|
学術雑誌(原著)
|
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients 2019/04
|
|
145.
|
学術雑誌(原著)
|
Dual inhibition of MEK and p38 impairs tumor growth in KRAS-mutated non-small cell lung cancer 2019/03
|
|
146.
|
学術雑誌(原著)
|
Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer 2019/03
|
|
147.
|
学術雑誌(原著)
|
Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1 2019/03
|
|
148.
|
学術雑誌(原著)
|
Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas 2019/02
|
|
149.
|
学術雑誌(原著)
|
Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma 2019/02
|
|
150.
|
学術雑誌(症例報告)
|
Spontaneous aspiration of a long tree twig as foreign body 2019/02
|
|
151.
|
学術雑誌(症例報告)
|
Spontaneous aspiration of a long tree twig as foreign body. 2019/02
|
|
152.
|
学術雑誌(原著)
|
Prognostic Impact of β2 Adrenergic Receptor Expression in Surgically Resected Pulmonary Pleomorphic Carcinoma 2019/01
|
|
153.
|
学術雑誌(原著)
|
Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer. 1993/01/20
|
|
154.
|
学術雑誌(総説)
|
Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer. 1993/01/15
|
|
155.
|
学術雑誌(原著)
|
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer. 1993/01/01
|
|
5件表示
|
|
全件表示(155件)
|